SCHEMBL15076184

SCHEMBL15076184

COC(=O)c1ccc2c(cnn2Cc2cc(C(F)(F)F)ccc2O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 2/20 0.44
▸ PPARG P37231 2/20 0.44
▸ TLR2 O60603 1/20 0.41
▸ TLR1 Q15399 1/20 0.41
▸ ESRRA P11474 1/20 0.41
▸ HDAC2 Q92769 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ LCK P06239 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ XDH P47989 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ CYP11B1 P15538 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15057999 0.89 HDAC2 (0.46) EPHX2PPARGESRRAHDAC2MAPT
SCHEMBL15056899 0.84 KMO (0.46) EPHX2PPARGHDAC2LCKMAOA
SCHEMBL15076265 0.84 CA12 (0.41) EPHX2PPARGHDAC2LMNALCK
SCHEMBL15076250 0.84 PTGER1 (0.41) EPHX2PPARGHDAC2ALDH1A1HTT
SCHEMBL15057529 0.82 EPHX2 (0.48) EPHX2PPARGESRRAHDAC2LMNA
SCHEMBL16929796 0.81 EPHX2 (0.42) EPHX2PPARGESRRAHDAC2MAOA
SCHEMBL25412148 0.77 BRD4 (0.53) LMNAALDH1A1HTTNPC1MAPT
SCHEMBL30614171 0.77 BRD4 (0.53) LMNAALDH1A1HTTNPC1MAPT
SCHEMBL15052200 0.76 MAOA (0.49) EPHX2PPARGHDAC2MAOAMAOB
SCHEMBL15076275 0.76 KMO (0.47) LCKCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2021-07-22 — — US disclosed
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2021-04-27 — — US disclosed
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP disclosed
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-07-09 — — US disclosed
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2019-08-27 — — US disclosed
EP-3424904-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE Allergan, Inc. (US) 2019-01-09 — — EP disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
WO-2013096496-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 EPHX2 147/4885PPARG 44/4885TLR2 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback